Advertisement


Jason R. Westin, MD, FASCO, on Updated Safety and Efficacy From the SUNMO Trial in LBCL

ASCO 2026

Advertisement

Jason R. Westin, MD, FASCO, of The University of Texas MD Anderson Cancer Center, provides an update on the safety and efficacy data from the phase III SUNMO trial, which compared mosunetuzumab and polatuzumab vedotin vs rituximab, gemcitabine, and oxaliplatin in patients with relapsed or refractory large B-cell lymphoma (LBCL) (Abstract 7007).



Transcript

Disclaimer: This video transcript has not been proofread or edited and may contain errors.
SUNMO is a study comparing a new combination called mosunetuzumab and polatuzumab, or Mosun-Pola. Mosun-Pola is a combination of a bispecific antibody and an antibody-drug conjugate. That combination has looked very promising in patients with relapsed/refractory large B-cell lymphoma, and the SUNMO trial evaluated it in a randomized fashion against R-GemOx, a chemotherapy backbone that's used commonly around the world for patients with relapsed large cell lymphoma. We presented last year the initial results and published them in the Journal of Clinical Oncology, the initial primary analysis. But at this ASCO meeting, we're now presenting an important update to those results. What we've shown with longer follow-up is that Mosun-Pola is still superior to R-GemOx, and we're hopeful this will translate into approvals for Mosun-Pola so that this treatment can be available to patients both within the United States as well as globally if they have relapsed/refractory large B-cell lymphoma. Specifically, what we found in this trial was that in patients who have relapsed large cell lymphoma and are transplant ineligible, the combination of Mosun-Pola had an improvement in overall response rate, complete response rate, progression-free survival, and quality of life for the patients. Patients actually felt better and did better receiving this novel treatment versus chemotherapy. Mosun-Pola is given as an outpatient. The mosunetuzumab part can be given subcutaneously, the polatuzumab part is given intravenously, and it's a fixed-duration treatment. It's not something that has to go on for a long time. It's given for a prescribed number of cycles, and then that stops. And what we found is that it doubled the complete response rate and had a massive improvement in progression-free survival. The interim analysis of overall survival is presented as well, and those data need to mature a bit more to see if there's a true difference in overall survival. But thus far, the results show a very significant improvement in patient outcomes for Mosun-Pola. An important point about the SUNMO trial, as we look at the toxicity profile for Mosun-Pola, is that bispecific antibodies and CAR T-cell therapies have a toxicity called cytokine release syndrome, which can be quite difficult to manage in sites that don't have experience managing this. What we saw for Mosun-Pola was that more than 95% of patients did not have significant cytokine release syndrome, which is a major difference from other bispecific antibodies in the same space. So if community oncologists are looking to choose whether they should use treatment A or treatment B for their patient, the lack of significant toxicities for Mosun-Pola could be a significant advantage for using this regimen over other regimens. That very low rate of cytokine release syndrome will be favorable for patients. So the message that oncologists should take away from this video is that if they're looking for treatments for patients who are ineligible for standard-of-care stem cell transplant with relapsed large cell lymphoma, the bispecific antibody mosunetuzumab and the antibody-drug conjugate polatuzumab, Mosun-Pola, should be an option they should consider for their patients, especially when comparing it to chemotherapy like R-GemOx.

Related Videos

Breast Cancer

Nicholas C. Turner, MD, PhD, on ER-Positive, HER2-Negative Advanced Breast Cancer: persevERA BC Trial

Nicholas C. Turner, MD, PhD, of the Royal Marsden Hospital, Institute of Cancer Research, discusses results from the primary analysis of the persevERA BC trial, which investigated giredestrant plus palbociclib vs letrozole plus palbociclib as first-line therapy in patients with estrogen receptor (ER)-positive, HER2-negative locally advanced or metastatic breast cancer (Abstract LBA1006).

Gastrointestinal Cancer

Veronica Diermayr, PhD, on AI-Driven Prediction of N256-Glycosylated CEACAM5/6 Expression in Gastric and Esophageal Cancer

Veronica Diermayr, PhD, of EDDC and A*STAR, discusses the use of artificial intelligence (AI) driven strategy called H&E 2.0 in gastric and esophageal cancer. Researchers tested the feasibility of training deep-learning models on hematoxylin and eosin images of gastroesophageal carcinomas and their ability to predict EBC-129 antigen expression directly from these images. EBC-129 is an experimental antibody-drug conjugate that targets N256-glycosylated CEACAM5/6, which is highly expressed on solid tumors, including gastroesophageal cancers (Abstract 4018).

Gynecologic Cancers

Linda R. Mileshkin, MD, MBBS, FRACP, on Puxitatug Samrotecan for Endometrial or Ovarian Cancer

Linda R. Mileshkin, MD, MBBS, FRACP, of Peter MacCallum Cancer Centre, shares results from the phase I/IIA BLUESTAR study on the safety and efficacy of puxitatug samrotecan, a B7-H4–directed topoisomerase I inhibitor antibody-drug conjugate, in patients with endometrial cancer or ovarian cancer (Abstract 5515). 

Multiple Myeloma

Dor Abelman, BS, on Multiple Myeloma: cfDNA WGS vs Plasma Proteomics for Minimally Invasive MRD Assessment

Dor Abelman, BS, of the University of Toronto, reviews results of a comparison of two minimally invasive measurable residual disease (MRD) assays—BM-informed cfDNA whole-genome sequencing (cfWGS) and plasma proteomic MRD (EasyM)—in patients with multiple myeloma (Abstract 7546). 

Bladder Cancer

Gopa Iyer, MD, on LY4052031 for Advanced or Metastatic Urothelial Carcinoma

Gopa Iyer, MD, of Memorial Sloan Kettering Cancer Center, presents initial results from the phase I NEXUS-01 study, which evaluated LY4052031, an antibody-drug conjugate targeting Nectin-4, in patients with advanced or metastatic urothelial carcinoma (Abstract 4508). 

Advertisement

Advertisement




Advertisement